Tagged exoflo

Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries
Press Release

Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries

 Thirty-three Navy SEAL veterans were treated with a bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle isolate product (EVIP) for Osteoarthritis (OA) of the knee, shoulder, elbow, hip, ankle, or wrist. Read More
Direct Biologics Announces FDA Approval for Proceeding With Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome
Press Release

Direct Biologics Announces FDA Approval for Proceeding With Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome

 Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites Read More
ExoFlo™ From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment
Press Release

ExoFlo™ From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment

 Medical professionals report dramatic and consistent success in treating patients gravely ill with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) Read More
Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome
Press Release

Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome

 Fourth IND Application approval for investigational extracellular vesicle (EV) product ExoFlo Read More
Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy
Press Release

Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy

 Extracellular vesicle product ExoFlo clinical trials to address early-stage COVID-19. Read More
Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome
Press Release

Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome

 Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites Read More
Innovative Product ExoFlo™ From Direct Biologics Fulfills Unmet but Urgent Medical Need in COVID-19 Treatment
Press Release

Innovative Product ExoFlo™ From Direct Biologics Fulfills Unmet but Urgent Medical Need in COVID-19 Treatment

 Medical professionals report dramatic and consistent success in treating patients gravely ill with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) Read More
Direct Biologics Announces New Advanced Tool in Regenerative Medicine with Launch of AmnioWrap™ Placental Allograft
Press Release

Direct Biologics Announces New Advanced Tool in Regenerative Medicine with Launch of AmnioWrap™ Placental Allograft

 New Allograft Joins Market Leading ExoFlo™ Extracellular Vesicles in Direct Biologics Product Line Read More
Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19
Press Release

Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19

 The expanded Access Program provides a pathway for patients to gain access to treatment with ExoFlo outside of the active Phase II research clinical trial. Read More
Press Release

Direct Biologics Initiates Patient Enrollment in the Phase II EXIT COVID-19 Clinical Trial

 Phase II Clinical Trial Initiated for ExoFlo Extracellular Vesicles in the Treatment of COVID-19 Read More
Press Release

New Data Suggest ExoFlo is Poised for a Quantum Leap in the Fight Against COVID-19

 Read More
Press Release

Direct Biologics Receives FDA Approval to Initiate 'EXIT-COVID-19,' a Phase II Investigational New Drug Trial

 Read More